Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints
February 24, 2015 at 09:04 AM EST
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) ("Teva") announced today positive results from a Phase IIb study evaluating the ...
